case_images: PMC9294358_01
case_images: Treatment timeline of the patient. Progressive lesions are indicated by red arrows. PD, progressive disease; PR, partial response; SD, stable disease.
case_images: fonc-12-911961-g001.jpg
case_images: PMC9294358_01_fonc-12-911961-g001.jpg
case_images: f1
case_images: The workup was pursued by a computed tomography (CT) scan, which showed a right lung mass (3.6 cm x 3.7 cm), a hepatic lump (2.2 cm x 1.5 cm) next to the inferior vena cava, and enlarged retroperitoneal lymph nodes ( Figure 1 ). Unfortunately, on September 15, 2020, a whole-body CT scan showed a progressive disease with an increase in the diameter of the right lung lesion (4.6 cm x 4.2 cm) ( Figure 1 ). After 3 cycles of camrelizumab, the patient was evaluated as with partial response for both PSC (3.1 cm x 3.1 cm) and HCC (1.4 cm x 1.2 cm) on the basis of CT imaging on December 15, 2020 ( Figure 1 ). Both PSC and HCC were assessed as stable disease (SD) ( Figure 1 ). Unfortunately, on June 16, 2021, the patient was assessed as PD with an increase of live tumor (the longer diameter is 1.5 cm) associated with the rise of AFP ( Figure 2 ) and the significant enlargement of abdominal lymph nodes in a whole-body CT scan ( Figure 1 ). After 23 cycles of camrelizumab treatment, the efficacy was assessed as SD for PSC and HCC according to the CT scan image in the last follow-up ( Figure 1 ).
case_images: Changes of serum AFP level during camrelizumab treatment. AFP, alpha-fetoprotein.
case_images: fonc-12-911961-g002.jpg
case_images: PMC9294358_01_fonc-12-911961-g002.jpg
case_images: f2
case_images: Unfortunately, on June 16, 2021, the patient was assessed as PD with an increase of live tumor (the longer diameter is 1.5 cm) associated with the rise of AFP ( Figure 2 ) and the significant enlargement of abdominal lymph nodes in a whole-body CT scan ( Figure 1 ).